Pulmonary fibrosis is not contagious. You cannot catch it from another person, and you cannot pass it to anyone else. It is not caused by a virus, bacterium, or any other infectious agent. The disease develops when lung tissue becomes scarred and thickened, a process driven by the body’s own faulty healing response rather than by a pathogen that could spread between people.
Why People Wonder About Contagion
The confusion is understandable. Pulmonary fibrosis shares several visible symptoms with contagious respiratory diseases like tuberculosis and pneumonia: a persistent cough, shortness of breath, chest tightness, and reduced ability to exercise. Someone watching a loved one struggle to breathe and cough frequently might instinctively worry about catching whatever is causing it. But the similarity ends at the surface. Tuberculosis is caused by bacteria that travel through the air. Pneumonia often starts with a virus or bacterium. Pulmonary fibrosis has an entirely different origin.
What Actually Causes the Scarring
In pulmonary fibrosis, the lungs respond to some form of damage or irritation by producing excess scar tissue. Specialized cells called fibroblasts go into overdrive, laying down collagen and other structural proteins far beyond what’s needed for normal repair. Over time, this scar tissue stiffens the lungs and makes it progressively harder to get oxygen into the bloodstream. The process is internal, driven by signaling molecules in the body that regulate cell growth and tissue repair. No outside organism is involved.
The triggers for this abnormal scarring vary widely. Known causes include:
- Environmental and occupational exposures: Asbestos, silica dust, metal dust (nickel, iron, aluminum), and wood dust can all damage lung tissue over years of repeated exposure. Roughly one in four cases of the idiopathic form may actually trace back to workplace dust and chemical inhalation, based on large analyses of occupational risk.
- Autoimmune diseases: Conditions like rheumatoid arthritis, lupus, and scleroderma can trigger chronic inflammation in the lungs that eventually leads to scarring.
- Medications and radiation: Certain drugs used for heart rhythm problems, infections, or cancer treatment, along with radiation therapy to the chest, can cause lung fibrosis as a side effect.
- Smoking: Long-term smoking increases the risk significantly.
In the majority of cases, no specific cause is ever identified. When that happens, the condition is called idiopathic pulmonary fibrosis, or IPF. “Idiopathic” simply means the origin is unknown.
The Role of Genetics
Some families carry gene mutations that make their members more vulnerable to developing pulmonary fibrosis. Research from Vanderbilt University’s Familial Pulmonary Fibrosis Registry found that about 8% of people with familial forms of the disease had mutations in genes responsible for maintaining telomeres, the protective caps on the ends of chromosomes. When these genes don’t work properly, telomeres shorten prematurely, and tissues that need to regenerate frequently, including lung tissue, become more susceptible to damage.
This genetic component is inherited, not infectious. A family member who develops pulmonary fibrosis passed along a gene variant, not a germ. Even people who carry these mutations don’t always develop the disease, though their shortened telomeres may put them at higher risk.
How It Differs From Infectious Lung Disease
Doctors can distinguish pulmonary fibrosis from infectious conditions through imaging. A high-resolution CT scan of the lungs reveals a distinctive pattern: scar tissue concentrated in the lower portions and outer edges of the lungs, with a characteristic “honeycombing” appearance of clustered tiny air spaces surrounded by thick walls. This pattern has a 90 to 100% accuracy rate for confirming the specific type of scarring seen in IPF. Infections like pneumonia or tuberculosis look completely different on imaging, typically showing fluid-filled areas, cavities, or patchy inflammation rather than structured scar tissue.
Why Infections Still Matter for Patients
While pulmonary fibrosis itself isn’t contagious, people living with the disease are more vulnerable to respiratory infections like influenza, COVID-19, and bacterial pneumonia. Scarred lungs have weakened defenses against invading pathogens, and the consequences of catching even a routine respiratory infection can be severe. Studies show that respiratory infections requiring hospitalization in people with IPF carry a mortality risk comparable to an acute flare-up of the disease itself. This vulnerability is one reason people with pulmonary fibrosis are often encouraged to stay current on vaccinations and take precautions during cold and flu season.
Disease Progression and Treatment
Pulmonary fibrosis is a progressive condition. The scarring doesn’t reverse, and for most people, lung function gradually declines over time. Without treatment, the median survival for idiopathic pulmonary fibrosis is between three and five years from diagnosis, though individual trajectories vary considerably. Some people remain relatively stable for years, while others experience faster decline.
Three FDA-approved antifibrotic medications are currently available for IPF: nintedanib, pirfenidone, and the more recently approved nerandomilast. These drugs don’t cure the disease or reverse existing scarring, but they slow the rate at which new scar tissue forms. They are approved for use across mild, moderate, and severe stages of the disease. For people whose lung function deteriorates significantly despite medication, lung transplantation may be considered.
Pulmonary rehabilitation, which combines supervised exercise training with breathing techniques and education, helps many patients maintain their activity levels and quality of life longer than they otherwise would. Supplemental oxygen becomes necessary for some people as the disease progresses and the lungs can no longer transfer enough oxygen on their own.